The Janus kinase (JAK) inhibitor Rinvoq (upadacitinib) from AbbVie has a current indication for moderate to severe active rheumatoid arthritis for patients with an inadequate response or intolerance to the immunosuppressant methotrexate.
Rinvoq is seeking expanded approval for the drug to treat moderate to severe atopic dermatitis (AD), which is a form of eczema.
Earlier this year, FDA extended the review period for the proposed use of Rinvoq for atopic dermatitis. European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), however, issued a positive recommendation with respect to the use of the drug to treat AD in adults and adolescents.
Filed Under: Rheumatology